The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.

Key facts

Study ID

NCT00002311

Run by

Mucos Pharma GmbH and Co

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV seropositivity with CD4 counts between 250 and 400 cells/mm3.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Known hypersensitivity to hydrolytic enzymes such as Wobenzym.
• Known sensitivity to lactose.
• Presumption that the patient will not comply with the dosing schedule or follow-up appointments.
• Concurrent Medication:
• Excluded:
• Concurrent use of immunosuppressive therapy or steroids.

Where it is running

• Saint Luke's - Roosevelt Hosp Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.